Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX(Modified Folinic Acid, Fluorouracil, and Oxaliplatin) in Hepatocellular Carcinoma With High-risk Recurrence Factors：A Single-center, Phase II, Single-arm, Prospective Study

NCT07337421 is registered in ClinicalTrials.gov with Northern Jiangsu People's Hospital as lead sponsor.

NCT NCT07337421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07337421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX(Modified Folinic Acid, Fluorouracil, and Oxaliplatin) in Hepatocellular Carcinoma With High-risk Recurrence Factors：A Single-center, Phase II, Single-arm, Prospective Study
Lead sponsor
Northern Jiangsu People's Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
September 1, 2025
Completion date
December 1, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc)